Methylene blue for refractory hypotension: A case report

AANA Journal

Volumn 76, Issue 4, 2008, Pages 271-274

  Weissgerber, Alicia J ^a  

^a Naval Hospital Camp Lejeune   (United States)

Author keywords

Anaphylaxis; Hypotension; Methylene blue; Nitric oxide

Indexed keywords

METHYLENE BLUE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; VASOACTIVE AGENT; VASOPRESSIN;

AGED; ANAPHYLAXIS; ARTICLE; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC DYSFUNCTION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SUBSTITUTION; GENERAL ANESTHESIA; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; MUSCLE RELAXATION; POSTOPERATIVE PERIOD;

AGED; ANAPHYLAXIS; ANESTHESIA, GENERAL; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CARDIOPULMONARY BYPASS; CEFAZOLIN; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; HYPOTENSION; MALE; METHYLENE BLUE; NITRIC OXIDE SYNTHASE; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 49749085204     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg. 2003;125(2):426-427.
2. Viaro F, Dalio, MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: Should methylene blue be the treatment of choice? Chest. 2002;122(3):1061-1066.
3. Maslow AD, Stearns G, Batula P, Schwarts CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg. 2006;103(1):2-8.
4. Grayling M, Deakin CD. Methyline blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg. 2003:125(2):426-427.
5. Cited by: Sparicio D, Landoni G, Zangrillo A. Angiotensin-converting enzyme inhibitors predispose to hypotension refractory to norepinephrine but responsive to methylene blue [editorial]. J Thorac Cardiovasc Surg. 2004;127(2):456-427.
6. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77(2):496-499.
7. Shanmugam G. Review: vasoplegic syndrome - the role of methylene blue. Eur J Cardiothorac Surg. 2005;28(5):705-710.
8. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg. 2002;94(4):824-829.
9. Peer G, Itzhakov E, Wollman Y, et al. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant. 2001;16(7):1436-1441.
10. Kalambokis G, Economou M, Fotopoulos A, et al. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Dis Sci. 2005;50(10):1771-1777.
11. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993;45(2):367-374.
12. Taylor K, Holtby H. Methylene blue revisited: Management of hypotension in a pediatric patient with bacterial endocarditis. J Thorac Cardiovasc Surg. 2005;130(2):566.
13. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Feletou M. Nitric oxide and inactivation of the endothelium-dependent contracting factor released by acetylcholine in spontaneously hypertensive rat. J Cardiovasc Pharmacol. 2004;43(6):815-820.